Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Junchen ChenShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA 92093.
Ming XuInstitute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093.
Yuan LiuShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA 92093.
Fatemeh HadiInstitute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093.
Shuanghong XueInstitute of Engineering in Medicine, University of California San Diego, La Jolla, CA 92093.
Shu ChienShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA 92093.ORCID 0000-0003-0332-285X
Sheng ZhongShu Chien-Gene Lay Department of Bioengineering, University of California San Diego, La Jolla, CA 92093.ORCID 0000-0001-6419-7453
Funding
Extremely high-throughput mapping of protein, RNA, and chromatin interactions in health and diseaseDP1DK126138 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZHONG, SHENG · 2020 to 2024
$3.7M
Single Cell Tracking of 3D Epigenetic Landscape Evolution During Embryonic DevelopmentR01HD107206 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Yingxiao Wang, Sheng Zhong · 2022 to 2026
$3.2M
Revealing protein-protein interactions and RNA-protein interactions at genome-scale in two weeksR01GM138852 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZHONG, SHENG · 2020 to 2023
$1.5M
Reducing Misdiagnosis in Alzheimer's Disease: AI-Driven Biomarker IdentificationF32AG094189 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LIU, YUAN · 2025 to 2025
$83k
HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) R01HD107206HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) DP1DK126138HHS | NIH | National Institute of General Medical Sciences (NIGMS) R01GM138852HHS | NIH | National Institute on Aging (NIA) F32AG094189NIA NIH HHS F32 AG094189
6 · The paper itself
Abstract
Pathological progression in sporadic Alzheimer's disease (sAD) initiates with an early rise in soluble amyloid-β (Aβ), preceding plaque formation and neurodegeneration. However, the molecular event triggering this initial accumulation remains unknown. We report that phosphoglycerate dehydrogenase (PHGDH), a consistent biomarker of prodromal sAD, drives Aβ production through a previously unrecognized RNA-binding function. Specifically, PHGDH binds the 3'UTR of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
RNA-binding activity of PHGDH drives amyloid-beta production in a human brain organoid model of sporadic Alzheimer's disease. · full record | OpenQuestion